» Articles » PMID: 35651598

Administration of Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats

Overview
Journal Res Rep Urol
Publisher Dove Medical Press
Specialty Urology
Date 2022 Jun 2
PMID 35651598
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Benign prostatic hyperplasia (BPH) is a major chronic disease affecting men, and the therapeutic agents currently used to manage it have significant side effects. As a result, an alternative medicine with improved therapeutic properties with no side effects is desperately needed. The current investigation aims to study whether the seed extracts (ethanolic-A, hydroalcoholic-B, and aqueous-C) have inhibitory potential on testosterone propionate (TP)-induced BPH in Wistar rats.

Methods: Wistar rats (male) were randomly allocated to one of five groups: control, BPH (TP-3 mg/kg, subcutaneously daily), low dose (TP + seed extracts - 200 mg/kg body weight), high dose (TP + seed extracts - 400 mg/kg body weight), and standard drug (TP + finasteride - 10 mg/kg body weight). At the end of drug treatment, the rats were sacrificed and their serum and prostates were taken for biochemical and histological studies.

Results: seed extracts treatment significantly decreased prostate weight and prostatic index in rats with TP-induced BPH. The seed extracts exhibited a potent inhibitory effect on dihydrotestosterone (DHT) in serum and prostate. In addition, the PSA level in the serum showed a noteworthy decrease in comparison with the BPH group. Histopathological examination also indicated that extracts improved the tissue morphology of the prostate significantly. Out of three extracts tested, ethanolic and hydroalcoholic extract recorded significant effect. Finally, liquid chromatography quadrupole time-of-flight mass spectrometry (LC/MS-QTOF) analysis showed that the major compounds present in the extracts were tocopherols, fucosterol, linoleic acid, β-amyrin, β-sitosterol, campesterol, cassane furanoditerpene, norcassane furanoditerpene and other diterpenes.

Conclusion: Thus, seed extracts could be a potential source for the formulation of new drug for managing BPH. To the best of our knowledge, this is the first scientific animal investigation into the use of seed extract for the management of BPH.

Citing Articles

Fabrication and Optimization of a Silodosin In Situ-Forming PLGA Implants for the Treatment of Benign Prostatic Hyperplasia: In Vitro and In Vivo Study.

Husseini R, Ibrahim T, Hamed E, Gomaa E, Faisal M, Wan G Pharmaceutics. 2024; 16(11).

PMID: 39598487 PMC: 11597075. DOI: 10.3390/pharmaceutics16111364.


Fucoidan Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Rats.

Shanmugasundaram D, Dwan C, Wimmer B, Srivastava S Res Rep Urol. 2024; 16:283-297.

PMID: 39498260 PMC: 11532999. DOI: 10.2147/RRU.S478740.


Antimicrobial potential of Hippocratea Indica Willd. Acetone Leaf fractions against Salmonella Typhi: an in vitro and in silico study.

Owolabi A, Akpor O, Ndako J, Owa S, Oluyori A, Oludipe E Sci Rep. 2024; 14(1):25222.

PMID: 39448699 PMC: 11502822. DOI: 10.1038/s41598-024-75796-1.


Diacerein provokes apoptosis, improves redox balance, and downregulates PCNA and TNF-α in a rat model of testosterone-induced benign prostatic hyperplasia: A new non-invasive approach.

Rasheed R, Sadek A, Khattab R, Elkhamisy F, Abdelfattah H, Elshaer M PLoS One. 2023; 18(11):e0293682.

PMID: 37943844 PMC: 10635502. DOI: 10.1371/journal.pone.0293682.


A semi purified hydroalcoholic fraction from seeds causes ergosterol biosynthesis inhibition in resulting in cell membrane damage.

Sasidharan S, Nishanth K, Nair H Front Pharmacol. 2023; 14:1189241.

PMID: 37377930 PMC: 10291067. DOI: 10.3389/fphar.2023.1189241.


References
1.
Arena A, Kassuya C, Alves Fernandes G, Scarano W . Toxic versus Therapeutic Effects of Natural Products on Reproductive Disorders. Evid Based Complement Alternat Med. 2019; 2019:9791506. PMC: 6885820. DOI: 10.1155/2019/9791506. View

2.
Thorpe A, Neal D . Benign prostatic hyperplasia. Lancet. 2003; 361(9366):1359-67. DOI: 10.1016/S0140-6736(03)13073-5. View

3.
Henry G, Malewska A, Mauck R, Gahan J, Hutchinson R, Torrealba J . Molecular pathogenesis of human prostate basal cell hyperplasia. Prostate. 2017; 77(13):1344-1355. PMC: 5580247. DOI: 10.1002/pros.23394. View

4.
Xin Q, Kwon M, Lee J, Kim K, Chen H, Campos M . Gamma Irradiated Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Downregulating 5-Alpha Reductase and Restoring Testosterone in Rats. Molecules. 2019; 24(21). PMC: 6864434. DOI: 10.3390/molecules24213981. View

5.
Lee Y, Lee J, Park J, Seo S, Chung J, Yoo T . Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol. 2016; 57(6):424-430. PMC: 5109794. DOI: 10.4111/icu.2016.57.6.424. View